Daily Stock Analysis, BMY, Bristol-Myers Squibb Co, priceseries

Bristol-Myers Squibb Co. Daily Stock Analysis
Stock Information
Open
60.40
Close
60.63
High
61.34
Low
60.22
Previous Close
60.15
Daily Price Gain
0.48
YTD High
69.75
YTD High Date
Aug 23, 2021
YTD Low
57.75
YTD Low Date
Mar 4, 2021
YTD Price Change
0.17
YTD Gain
0.28%
52 Week High
69.75
52 Week High Date
Aug 23, 2021
52 Week Low
55.47
52 Week Low Date
Oct 29, 2020
52 Week Price Change
4.13
52 Week Gain
7.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 2. 2017
44.14
Mar 7. 2017
48.76
22 Trading Days
10.49%
Link
LONG
Aug 22. 2017
51.12
Oct 16. 2017
57.30
38 Trading Days
12.08%
Link
LONG
Oct 17. 2019
49.70
Nov 18. 2019
54.89
22 Trading Days
10.44%
Link
LONG
Dec 3. 2019
54.76
Jan 3. 2020
59.86
21 Trading Days
9.32%
Link
LONG
Mar 26. 2020
49.89
Apr 30. 2020
58.88
24 Trading Days
18.00%
Link
Company Information
Stock Symbol
BMY
Exchange
NYSE
Company URL
http://www.bms.com
Company Phone
2125464000
CEO
Giovanni Caforio
Headquarters
New York
Business Address
345 PARK AVE, NEW YORK, NY 10154
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0000014272
About

Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.